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Overexpression of PVR and PD‑L1 
and its association with prognosis 
in surgically resected squamous cell 
lung carcinoma
Jii Bum Lee1,2, Min Hee Hong1, Seong Yong Park3, Sehyun Chae4, Daehee Hwang5, 
Sang‑Jun Ha6, Hyo Sup Shim7* & Hye Ryun Kim1*
Targeting T‑Cell Immunoreceptor with Ig and ITIM domain‑poliovirus receptor (PVR) pathway is a 
potential therapeutic strategy in lung cancer. We analyzed the expression of PVR and programmed 
death ligand‑1 (PD‑L1) in surgically resected squamous cell lung carcinoma (SQCC) and determined 
its prognostic significance. We collected archival surgical specimens and data of 259 patients with 
SQCC at Yonsei Cancer Center (1998–2020). Analysis of variance was used to analyze the correlations 
between PVR and PD‑L1 expression and patient characteristics. Kaplan–Meier curves were used to 
estimate recurrence‑free survival (RFS) and overall survival (OS). Most patients were male (93%); 
the majority were diagnosed with stage 1 (47%), followed by stage 2 (29%) and stage 3 (21%). 
Overexpression of PVR resulted in a significantly shorter median RFS and OS (P = 0.01). PD‑L1 
expression was not significant in terms of prognosis. Patients were subdivided into four groups 
based on low and high PVR and PD‑L1 expression. Those expressing high levels of PVR and PD‑L1 
had the shortest RFS (P = 0.03). PVR overexpression is associated with a poor prognosis in surgically 
resected SQCC. Inhibition of PVR as well as PD‑L1 may help overcome the lack of response to immune 
checkpoint monotherapy.
Squamous cell lung carcinoma (SQCC) accounts for 20–30% of all non-small cell lung cancers (NSCLCs)1. With 
distinct clinicopathological features, such as a lack of targetable mutations, higher incidence in older individuals, 
and advanced or metastatic disease at diagnosis, patients with SQCC have a shorter lifespan than those with other 
NSCLC  subtypes2–4. Despite surgical resection, many patients with NSCLC experience  relapse5. In surgically 
resected NSCLC (pathological stages IA–IIB), the 5-year survival rate is approximately 40–70%, but drops to 
13% and 5% for stage IIIA and IIIB disease,  respectively6.
Prior to immunotherapy, the first-line treatment options for advanced SQCC were limited to platinum-
doublet chemotherapy, with a median survival of 8–11  months7. The advent of pembrolizumab, a programmed 
cell death protein-1 (PD-1) inhibitor, revolutionized the first-line treatment options for both patients with 
squamous and non-squamous NSCLC with programmed death ligand-1 (PD-L1) expression levels of ≥ 50%8. 
However, only 30% of patients with advanced NSCLC exhibit high levels of PD-L1 expression and are eligible 
for treatment with  pembrolizumab8,9.
Recently, adding pembrolizumab to chemotherapy resulted in a significant survival advantage for patients 
with advanced SQCC in first-line settings, regardless of PD-L1  expression10. Although the PD-L1 tumor propor-
tion score is currently a biomarker for first-line treatment using pembrolizumab, the predictive role of PD-L1 in 
combination treatment needs further validation since patients across all categories of PD-L1 expression showed 
improved outcomes with combination treatment. Other combination treatments with immune checkpoint inhibi-
tors—such as ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated protein-4—and 
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chemotherapy did not improve overall survival (OS) in patients with metastatic squamous or non-squamous 
 NSCLC11.
Other checkpoint receptor blockers that modulate immune cell activation are currently under investigation 
since a significant proportion of patients do not respond to  immunotherapy12. Among checkpoint blockers, T-cell 
immunoglobulin and ITIM domain (TIGIT) binds to poliovirus receptor (PVR). TIGIT is enriched on T-cells, 
such as regulatory T-cells, type 1 regulatory T-cells, memory T-cells, exhausted CD8 + T-cells, natural killer 
T-cells, and natural killer  cells13,14. Mouse models have shown that TIGIT/PVR binding induces immune evasion 
of tumor cells, one of the key hallmarks of  cancer15,16. Levels of PVR are usually low (or PVR is not expressed) 
in normal tissues, but are high in tumor cells. PVR expression is associated with the invasion, migration, and 
proliferation of tumor  cells17. Overexpression of PVR is observed in multiple malignancies, and tumors express-
ing high levels of PVR are also associated with poor  prognosis18–20.
Recently, several clinical trials have evaluated the efficacy of blocking the TIGIT/PVR axis in solid cancers 
such as  NSCLC21. Tiragolumab, an anti-TIGIT antibody, in combination with atezolizumab, an anti-PD-L1 
agent, showed a promising treatment response and a manageable toxicity profile in first-line NSCLC treatment. 
Compared to monotherapy (atezolizumab), combination therapy improved the objective response rate (31.3% 
vs. 16.2%) and median progression-free survival (5.4 vs. 3.6 months). These results strongly suggest that the 
TIGIT/PVR axis may be a clinically useful target for treating patients with NSCLC.
Despite increasing evidence of the involvement of the TIGIT/PVR axis, few studies have addressed the 
prognostic role of  PVR22. Therefore, we aimed to assess PVR expression in surgically resected SQCC tissues to 
determine its relationship with PD-L1. We evaluated the correlations of PVR and PD-L1 expression with clin-
icopathological factors and determined their prognostic implications for survival outcomes in SQCC (Fig. 1).
Results
PVR expression in SQCC (The Cancer Genome Atlas [TCGA] data). We analyzed TCGA RNA-
sequencing data of gene expression profiles in SQCC to identify the co-expression patterns of immune check-
point ligands (ICLs)23. Figure 2a, b consists of two main clusters, including the PD-L1 (CD274) cluster of 10 
other ICLs (CD48/80/86, BTN2A2/3A1, TIMD4, VSIG4, PDCD1LG2, TNFRSF14, and LGALS9) and the PVR 
cluster of PVR, NECTIN2, and CD276. Clustering analysis showed no correlation between the PD-L1 (CD274) 
cluster (red boxes) and the PVR cluster (blue boxes). Scatter plot also showed no correlation between the PD-L1 
(CD274) cluster and the PVR cluster (Fig. 2c).
According to the TCGA data, PVR was expressed independently of PD-L1 expression in SQCC. We also 
analyzed the survival difference for both high expression and low expression of PD-L1 and PVR but found no sig-
nificant differences in OS between the groups with high and low PD-L1 (P = 0.91) and PVR expression (P = 0.55; 
Fig. 2d). We further categorized patients into four groups depending on PD-L1 and PVR expression: PD-L1hi/
PVRlo, PD-L1lo/PVRlo, PD-L1hi/PVRhi, and PD-L1lo/PVRhi (Fig. 2e). Similarly, no significant differences were 
found between the four subgroups using multivariate analyses. There was a trend for the PD-L1hi/PVRhi group to 
have the worst survival rate, indicating that high expression of PD-L1 and PVR may contribute to poor prognosis.
Baseline clinicopathological characteristics. In total, 259 patients were included (see Supplementary 
Table S1 online). Patients were distributed evenly across the age groups (< 65 years, 47%; ≥ 65 years, 53%). Most 
patients were male (93%, n = 241). When classified according to American Joint Committee on Cancer (seventh 
edition) stage, the majority of patients were initially diagnosed with stage 1 disease (47%, n = 122), followed by 
Figure 1.  Programmed death ligand-1 (PD-L1) and poliovirus receptor (PVR) expression analysis using 
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stage 2 (29%, n = 76) and stage 3 disease (21%, n = 54). Pleural involvement and lymphovascular invasion were 
observed in 26% (n = 68) and 11% (n = 28) of patients, respectively. Most patients had a history of smoking, 
with 41% (n = 106) being smokers at the time of hospitalization; 44% (n = 114) were former smokers. Adjuvant 
chemotherapy and radiotherapy were administered to 85% (n = 221) and 17% (n = 44) of patients, respectively.
Table 1 shows no significant differences in age, sex, pathological T/N stage, EGFR and KRAS mutation, pleural 
involvement, lymphovascular invasion, smoking status, and adjuvant chemotherapy and radiotherapy among 
the different groups (grouped according to PD-L1 and PVR expression). The distribution of PD-L1, PVR, and 
 CD8+ expression is depicted in Supplementary Fig. S3 online.
Association between PVR expression and survival. In conjunction with the survival curves drawn 
using TCGA data of lung squamous cell carcinoma (Fig. 2c), we analyzed the median recurrence-free survival 
(mRFS) and median OS (mOS) of patients according to high or low expression levels of PD-L1 (CD274) and 
PVR (Fig. 3). High PVR expression was associated with inferior mRFS and mOS. The mRFS was 4.8 months for 
high PVR expression and 10.0 years for low PVR expression (hazard ratio [HR]: 1.54, 95% confidence interval 
[CI]: 1.15–2.07; P = 0.01) (Fig. 3a). The corresponding mOS values were 5.6 and 11.2 years, respectively (HR: 
1.45, 95% CI: 1.10–2.00; P = 0.01) (Fig. 3b). In contrast, high PD-L1 expression or high  CD8+ expression was not 
associated with either poor mRFS or mOS (Fig. 3c, d and see Supplementary Fig. S4 online).
Association of PVR and PD‑L1 expression with clinical characteristics. Patients were further cat-
egorized into four groups depending on the expression levels of both PD-L1 and PVR, based on the median 
expression level: PD-L1hi/PVRlo (n = 37, 14%), PD-L1lo/PVRlo (n = 95, 37%), PD-L1hi/PVRhi (n = 33, 13%), and 
PD-L1lo/PVRhi (n = 94, 36%).
The comparison of mRFS and mOS between these subgroups (depicted in Fig. 4) showed that the PD-L1hi/
PVRhi group had the shortest mRFS of 3.7 years, followed by the PD-L1lo/PVRhi, PD-L1lo/PVRlo, and PD-L1hi/
PVRlo groups (P = 0.03). The PD-L1hi/PVRhi group had a tendency for the shortest mOS, although the result was 
not significant (P = 0.06). Subgroup analysis showed that the PD-L1hi/PVRlo group had improved mOS compared 
to the PD-L1lo/PVRhi group (HR: 2.43, 95% CI: 1.46–3.96; P = 0.04).
Figure 2.  Co-expression patterns of immune checkpoint ligands (ICLs) and immune checkpoint receptors in 
The Cancer Genome Atlas data of lung squamous cell carcinoma. (a) Heatmap showing Spearman’s correlation 
coefficients for all pairs of ICLs. The dendrogram shows the results of hierarchical clustering of ICLs based on 
the correlation coefficients using Euclidean distance as a dissimilarity measure and the single linkage method. 
Red boxes represent programmed death ligand-1 (PD-L1/CD274); blue boxes represent poliovirus receptor 
(PVR). (b) Gene expression patterns of ICLs among four patient groups: (1) PD-L1hi/PVRlo, (2) PD-L1lo/PVRlo, 
(3) PD-L1hi/PVRhi, and (4) PD-L1lo/PVRhi. Red represents increased median expression and blue represents 
decreased median expression levels of each ICL. The colored bar shows the gradient of  log2 fold-changes in 
expression levels. (c) Scatter plot showing patterns of PD-L1 and PVR. (d) Kaplan–Meier analysis of overall 
survival according to high and low PD-L1 (CD274) and PVR expression, respectively. (e) Multivariate analyses 
of four patient groups show no statistically significant differences between the groups.
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Table 1.  Comparison of clinical characteristics between patients based on PVR and PD-L1 expression levels. 
AJCC, American Joint Committee on Cancer; PD-L1, programmed death ligand-1; PVR, poliovirus receptor; 










P-valuen % n % n % n %
Number of patients 37 14 95 37 33 13 94 36
Age, years 0.99
 < 65 18 49 45 47 15 45 45 48
 ≥ 65 19 51 50 53 18 55 49 52
Sex 0.91
 Male 35 95 87 92 31 94 88 94
 Female 2 5 8 8 2 6 6 6
Pathological T stage 0.36
 T1 2 5 19 20 5 15 9 10
 T2 29 78 63 66 21 64 62 66
 T3 5 14 11 12 6 18 19 20
 T4 1 3 2 2 1 3 4 4
Pathological N stage 0.48
 N0 17 46 57 60 21 64 47 50
 N1 15 40 22 23 5 15 29 31
 N2 5 14 15 16 7 21 17 18
 N3 0 0 1 1 0 0 1 1
AJCC stage (seventh edition) 0.38
 I 15 40 49 52 16 48 42 45
 II 15 40 28 29 9 28 24 26
 IIIA 5 14 17 18 7 21 25 27
 IIIB 1 3 1 1 1 3 3 2
 IV 1 3 0 0 0 0 0 0
Pleural involvement 0.63
 Positive 8 22 23 24 8 24 29 31
 Negative 29 78 72 76 25 76 65 69
Lymphovascular invasion 0.76
 Positive 3 8 9 9 5 16 11 12
 Negative 34 92 86 91 28 84 83 88
EGFR mutation
 Yes 0 0 2 2 0 0 2 2 0.31
 No 16 43 21 22 16 48 15 16
 Unknown 21 57 72 76 17 52 77 82
KRAS mutation
 Yes 0 0 0 0 0 0 0 0 0.31
 No 14 38 22 23 15 45 17 18
 Unknown 23 62 73 77 18 55 77 82
Smoking status 0.58
 Never-smoker 7 19 15 16 2 6 15 16
 Former smoker 16 43 46 48 14 42 38 40
 Current smoker 14 38 34 36 17 52 41 44
Adjuvant therapy
Adjuvant chemotherapy 0.69
 Yes 33 89 78 82 29 88 81 86
 No 4 11 17 18 4 12 13 14
Adjuvant radiotherapy 0.36
 Yes 6 16 13 14 4 12 21 22
 No 31 84 82 86 29 88 73 78
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Figure 3.  Kaplan–Meier analysis of recurrence-free survival (RFS) and overall survival (OS) by poliovirus 
receptor (PVR) and programmed death ligand-1 (PD-L1) expression. HR, hazard ratio; CI, confidence interval.
Figure 4.  Kaplan–Meier analysis of (a) recurrence-free survival (RFS) and (b) overall survival (OS) by 
poliovirus receptor (PVR) and programmed death ligand-1 (PD-L1) expression. Patients were subdivided into 
four groups depending on their PD-L1 and PVR expression: (1) PD-L1hi/PVRlo, (2) PD-L1lo/PVRlo, (3) PD-L1hi/
PVRhi, and (4) PD-L1lo/PVRhi.
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Univariate and multivariate analyses of factors affecting survival. Univariate and multivariate 
analyses included factors such as age (< 65 vs. ≥ 65 years), sex, smoking status (non-smoker vs. smoker), cancer 
stage (I–II vs. III–IV), and PD-L1 and PVR status (PD-L1hi/PVRlo vs. others). Other subgroups included the 
PD-L1lo/PVRlo, PD-L1hi/PVRhi, and PD-L1lo/PVRhi groups.
Univariate analyses of RFS revealed that age ≥ 65 years (HR: 0.57, 95% CI: 0.43–0.77; P = 0.01), smoking 
history (HR: 0.63, 95% CI: 0.40–0.99; P = 0.04), advanced stage (HR: 0.46, 95% CI: 0.33–0.63; P = 0.01), and 
PVR > 20 (HR: 0.66, 95% CI: 0.50–0.89; P = 0.01) were associated with worse outcomes (see Supplementary 
Table S2 online). With the exception of smoking status, these factors were also significant in multivariate analyses. 
Similarly, age ≥ 65 years (HR: 0.57, 95% CI: 0.42–0.77; P = 0.01), advanced stage (HR: 0.41, 95% CI: 0.30–0.57; 
P = 0.01), and PVR > 20 (HR: 0.68, 95% CI: 0.50–0.91; P = 0.01) were associated with worse OS. On multivariate 
analyses, we found that all these factors remained significant as independent factors (see Supplementary Table S3 
online). Overall, RFS and OS of surgically resected SQCC were affected by age, stage, and PVR expression. Of 
note, PD-L1 was not a prognostic factor for both RFS and OS in univariate and multivariate analyses. In contrast, 
high PVR expression was associated with short RFS and OS.
Discussion
In our study, we found that the PD-L1 and PVR clusters were independently expressed as per TCGA RNA-
sequencing data. In our cohort, PD-L1hi/PVRhi status was correlated with the worst RFS, signifying that both 
PD-L1 and PVR are important factors for the recurrence of surgically resected SQCC. Similarly, PD-L1hi/PVRhi 
status was also correlated with the shortest OS, although the result was not statistically significant. Subgroup 
analysis also showed that the PD-L1lo/PVRhi group had shorter OS than the PD-L1hi/PVRlo group, emphasizing 
the importance of PVR for OS, regardless of PD-L1 expression. Furthermore, multivariate analysis showed that 
high level of PVR expression was associated poor RFS and OS However, PD-L1 expression levels did not affect 
RFS or OS.
Currently, immunohistochemistry for PD-L1 is used to identify patients most likely to respond to immuno-
therapeutic agents, such as anti-PD-1 or anti-PD-L1  agents24. PD-L1 signaling blocks the T-cell response neces-
sary for cytokine secretion and regulates the antitumor response by inducing regulatory T-cell  differentiation25,26. 
Although targeting the PD-1/PD-L1 pathway with anti-PD-1 agents has shown reliable and robust results in 
metastatic and recurrent SQCC, some patients are unresponsive to these  treatments8–10. Therefore, there is an 
unmet need to effectively treat non-responders.
Recently, a phase 2 trial of administering 2 cycles of atezolizumab, an anti-PD-L1 monoclonal antibody in 
neoadjuvant setting for resectable stage IB-IIIB NSCLC, yielded clinically meaningful major pathologic response 
rate of 20%27. The role of PD-L1 as well as PVR in neoadjuvant setting is yet to be elucidated.
Accumulating evidence suggests that targeting single checkpoints, such as the PD-1/PD-L1 pathway is insuf-
ficient for eliciting an immune  response28,29. A better understanding of T-cell activity in combination with other 
checkpoint inhibitors may help overcome the lack of response due to the inhibition of immune activation. 
One potential mechanism is to block TIGIT, which interacts with  PVR30. PVR binds to TIGIT, which is highly 
expressed in natural killer cells, T-cells, and regulatory T-cells, and induces immune escape of tumor  cells31,32. 
Studies using mouse models have shown that the TIGIT/PVR axis is associated with inhibition of the prolifera-
tion, differentiation, and activation of T-cells and the activation of inhibitory T-cells (regulatory T-cells)13,33. 
Thus, targeting the TIGIT/PVR pathway may be a potential mechanism to overcome resistance to checkpoint 
inhibitors. Tiragolumab, an anti-TIGIT antibody, is a promising agent, which can be combined with atezolizumab 
to treat naïve, PD-L1-positive NSCLC.
There are few limitations to our study. First, our study was conducted retrospectively in a single center. The 
sole inclusion of Asian patients and the retrospective study design further limited the generalizability of our 
results. Validation using larger, prospective cohorts is warranted to bolster our findings. Second, our study 
lacked patients treated with immunotherapy after a systemic relapse, preventing the evaluation of the predictive 
roles of both PD-L1 and PVR. Identifying these factors in patients treated with immunotherapy in metastatic 
SQCC settings may help select those who may benefit from a combination of immunotherapeutic agents. Third, 
PD-L1 may possibly be underrepresented in some of the archival FFPE tissue blocks that date back to 1998. 
Indeed, studies have addressed that fresh biopsy samples better represent PD-L1  status34,35. However, PD-L1 
was not a prerequisite at the time of tissue collection for this cohort, and this study adequately represents long 
term follow-up data on RFS and OS in surgically resected SQCC. Studies with more recent tissue samples are 
needed to validate our findings.
To our knowledge, the prognostic role of PD-L1 in correlation with PVR in SQCC has not been validated in 
any other study. Our study focused on the independent expression of PD-L1 and PVR and showed that patients 
with both high PD-L1 and PVR expression had a short RFS. Since patients with surgically resected SQCC often 
experience both local and distant relapses, better systemic treatment options for recurrent SQCC should be 
available in the immunotherapy  era5.
In conclusion, overexpression of PVR is associated with poor prognosis in terms of RFS in surgically resected 
SQCC. Simultaneously targeting PD-L1 and the TIGIT/PVR axis with combination treatments may help over-
come the lack of treatment response to immune checkpoint monotherapy.
Methods
Ethics declarations. The study was conducted in accordance with the Declaration of Helsinki. All patients 
provided written informed consent. The study was approved by the Institutional Review Board of Yonsei Cancer 
Center (approval number: 4–2018-1161).
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Expression of immune checkpoint ligand and receptor genes. We retrieved data on SQCC from 
TCGA to conduct a correlative analysis of ICLs and immune checkpoint  receptors23. We collected data of nor-
malized fragments per kilobase of transcript per million mapped reads for analysis of the RNA-sequencing 
dataset and performed a correlation analysis of 26 ICLs using Spearman’s  correlation36. Using the hierarchical 
clustering method, we identified clusters of ICLs with strong co-expression patterns and selected two clusters 
that did not show correlations. Each ICL was categorized based on high (≥ 50th percentile) or low (< 50th per-
centile) expression of the target gene. The Kaplan–Meier method was used to calculate the OS, and Cox regres-
sion analysis was used for multivariate analysis.
Patient selection. Data of 259 patients diagnosed with SQCC at the Yonsei Cancer Center between January 
1998 and July 2020 were collected. The inclusion criteria for patient selection were surgically resected SQCC, 
archival tumor samples available for PVR and PD-L1 analysis, and availability of clinical data. Clinicopathologi-
cal variables, such as age, sex, stage, pleural involvement, lymphovascular invasion, mutations in the EGFR and 
KRAS genes, smoking status, and adjuvant treatment, were evaluated. The American Joint Committee on Cancer 
(seventh edition) guidelines for tumor–node–metastasis classification were used to determine cancer  stage37. 
An experienced pathologist (HSS) blinded to the clinical data reviewed and interpreted the pathology findings.
Tissue microarray. We selected two or three different areas per sample representing tumor areas and devel-
oped tissue microarrays. Using formalin-fixed paraffin-embedded blocks, we collected tissue cores (3 mm in 
diameter) and arranged them in recipient paraffin blocks using a trephine. All tissue microarray blocks con-
tained tumor lesions representing > 50% of the core, based on hematoxylin–eosin staining.
Immunohistochemistry. A Ventana Benchmark XT autostainer (Ventana Medical Systems, Tucson, AZ, 
USA) was used to perform immunohistochemistry on 4-µm tissue microarray sections. The sections were stained 
with an anti–PD-L1 (clone SP263, Ventana Medical Systems) rabbit monoclonal primary antibody using the 
OptiView DAB IHC Detection kit for the PD-L1 IHC  assay38. PVR antibody (rabbit monoclonal, cloneD8A5G, 
Cell Signaling Technology) was diluted to 1:100, treated, and incubated at 37 °C for 32 min for the PVR IHC 
assay. Using ultraview universal DAB Detection Kit (Ventana Medical Systems), the signals for PD-L1 and PVR 
were detected. Both the PD-L1 and PVR scores were interpreted as TPS according to the methods described in 
previous  studies9.
PD-L1 high and low expression status were determined according to the median cut-off value of 5% staining 
of tumor cells (see Supplementary Fig. S1 online). PVR expression was classified as high (> 20% TPS) or low 
(≤ 20% TPS) based on the median value (see Supplementary Fig. S1 online). Patients were then categorized into 
four groups depending on PD-L1 and PVR expression: PD-L1hi/PVRlo, PD-L1lo/PVRlo, PD-L1hi/PVRhi, and 
PD-L1lo/PVRhi (Fig. 1a–d).
For the  CD8+ analysis, the percentages of CD8 + lymphocytes (RTU, clone C8/144B (Dako, Glostrup, Den-
mark) compared with the total amount of nucleated cells in the stromal compartments were  assessed39.  CD8+ 
expression was also determined as high (≥ 10) or low (< 10) based on the median cutoff value of 10%.
Statistical analysis. The correlations between variables were analyzed using Fischer’s exact test for cat-
egorical variables and the sample t-test for continuous variables. We used the Kaplan–Meier method to calculate 
OS and RFS. RFS was defined as the time from the date of surgery to the date of recurrence, last follow-up, or 
death. OS was defined as the time between the date of diagnosis and the date of last follow-up or death. Cox 
regression with backward elimination method was used for multivariate analysis of OS. Statistical analyses were 
two-sided with P = 0.05 as the level of significance. All statistical analyses were performed using Statistical Pack-
age for the Social Sciences (version 25; IBM, Chicago, IL, USA) and GraphPad Prism 8.0 Software (GraphPad 
Software, Inc., San Diego, CA).
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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